Cecilia Bonolo DE Campos1,2, Gleidice Eunice Lavalle3, Lidianne Narducci Monteiro4, Gabriela Rafaela Arantes Pêgas1, Silvia Ligório Fialho5, Débora Balabram6, Geovanni Dantas Cassali7. 1. Laboratory of Comparative Pathology, Department of General Pathology, Federal University of Minas Gerais (UFMG), Belo Horizonte, Brazil. 2. Department of Veterinary Clinic and Surgery, School of Agricultural and Veterinary Sciences of the Sao Paulo State University (FCAV/UNESP), Jaboticabal, Brazil. 3. Department of Veterinary Clinic and Surgery, Veterinary School, Federal University of Minas Gerais (UFMG), Belo Horizonte, Brazil. 4. Veterinary Pathology Diagnostic Consultancy (Codivet), Vitória, Brazil. 5. Department of Pharmaceutical and Biotechnological Development, Fundação Ezequiel Dias, Belo Horizonte, Brazil. 6. Education and Research Institute Santa Casa BH, Belo Horizonte, Brazil. 7. Laboratory of Comparative Pathology, Department of General Pathology, Federal University of Minas Gerais (UFMG), Belo Horizonte, Brazil cassalig@icb.ufmg.br.
Abstract
BACKGROUND/AIM: The aim of the present study was to evaluate a multimodal approach for the treatment of canine malignant mammary gland neoplasms, including surgery, chemotherapy, thalidomide, and metronomic chemotherapy (MC). MATERIALS AND METHODS: Fifty-eight female dogs were submitted to four different treatments: surgery; surgery with chemotherapy; surgery with chemotherapy and thalidomide; and surgery with chemotherapy and metronomic chemotherapy and overall survival was evaluated. RESULTS: No statistical difference was found in the proliferative index and microvessel density of primary neoplasms and distant metastases following thalidomide treatment. Diffuse intense inflammatory infiltrate was predominant in primary tumors and diffuse moderate inflammatory infiltrate in metastatic lesions. No statistically significant difference was observed in median survival time (MST) between treatment groups when including all clinical stages (p=0.3177). However, animals diagnosed with distant metastasis treated with surgery and chemotherapy associated with thalidomide or MC presented longer MST when compared to animals treated only with surgery or surgery and chemotherapy (p<0.0001). CONCLUSION: The proposed multimodal therapy protocols including antiangiogenic and immunomodulatory therapies demonstrated a clinical benefit for patients in advanced clinical stages. Copyright
BACKGROUND/AIM: The aim of the present study was to evaluate a multimodal approach for the treatment of canine malignant mammary gland neoplasms, including surgery, chemotherapy, thalidomide, and metronomic chemotherapy (MC). MATERIALS AND METHODS: Fifty-eight female dogs were submitted to four different treatments: surgery; surgery with chemotherapy; surgery with chemotherapy and thalidomide; and surgery with chemotherapy and metronomic chemotherapy and overall survival was evaluated. RESULTS: No statistical difference was found in the proliferative index and microvessel density of primary neoplasms and distant metastases following thalidomide treatment. Diffuse intense inflammatory infiltrate was predominant in primary tumors and diffuse moderate inflammatory infiltrate in metastatic lesions. No statistically significant difference was observed in median survival time (MST) between treatment groups when including all clinical stages (p=0.3177). However, animals diagnosed with distant metastasis treated with surgery and chemotherapy associated with thalidomide or MC presented longer MST when compared to animals treated only with surgery or surgery and chemotherapy (p<0.0001). CONCLUSION: The proposed multimodal therapy protocols including antiangiogenic and immunomodulatory therapies demonstrated a clinical benefit for patients in advanced clinical stages. Copyright
Authors: S M Baidas; E P Winer; G F Fleming; L Harris; J M Pluda; J G Crawford; H Yamauchi; C Isaacs; J Hanfelt; M Tefft; D Flockhart; M D Johnson; M J Hawkins; M E Lippman; D F Hayes Journal: J Clin Oncol Date: 2000-07 Impact factor: 44.544
Authors: T Eisen; C Boshoff; I Mak; F Sapunar; M M Vaughan; L Pyle; S R Johnston; R Ahern; I E Smith; M E Gore Journal: Br J Cancer Date: 2000-02 Impact factor: 7.640